Biosimilars in pediatric rheumatology and their introduction into routine care
نویسندگان
چکیده
منابع مشابه
Biosimilars in rheumatology: understanding the rigor of their development
This article examines the current landscape of biosimilar development in rheumatology. As misperceptions about biosimilars exist regarding their comparability to the reference products for clinical use, we review the development paradigm with the goal of improving rheumatologists' understanding of the rigor with which biosimilars are developed. With an emphasis on European Union and US markets,...
متن کاملBiosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
Rheumatoid arthritis (RA) societal costs are high because the disease may cause not only restricted joint mobility, chronic pain, fatigue, and functional disability, but also psychological distress. Direct health care costs represent about one-fourth of all costs and are prevalently represented by in-patient care expenditures. The introduction of biologics disease-modifying anti-rheumatic drugs...
متن کاملUse of Biologics and Biosimilars in Rheumatology.
Prior to the availability of biologics, synthetic DMARDs (Disease modifying anti-rheumatic drugs) were the mainstay of the treatment in rheumatology. With the introduction of biologics, the scenario is changing to become more promising. These drugs have innovative mechanism of action, based on the targeted inhibition of specific molecular or cellular targets directly involved in disease pathoge...
متن کاملThe changing landscape of biosimilars in rheumatology
Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at th...
متن کاملBiosimilars in rheumatology: the wind of change.
The wind of change is blowing in rheumatology. Rheumatologists may soon be exposed to ‘biosimilars’ of the medicines they routinely use as the European Medicines Agency (EMA) has recently issued its final guideline on biosimilar monoclonal antibodies (mAbs)—a product class of utmost importance for rheumatologists—and a biosimilar infliximab is currently under evaluation for marketing authorisat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Immunology
سال: 2020
ISSN: 1521-6616
DOI: 10.1016/j.clim.2020.108447